ArticleAmerican journal of clinical pathology2012
Clinical and pathologic features of secondary acute promyelocytic leukemia.
Article in American journal of clinical pathology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Therapy-related acute promyelocytic leukemia: a systematic review.Medical oncology (Northwood, London, England) · 2013Pooled it
- Article
- An Update on Flow Cytometry Analysis of Hematological Malignancies: Focus on Standardization.Cancers · 2025Review
- Full spectrum flow cytometry in the clinical laboratory.International journal of laboratory hematology · 2023Review
- Article
- Optimizing outcomes in secondary AML.Hematology. American Society of Hematology. Education Program · 2022Article
- Therapy-related acute promyelocytic leukemia with FMS-like tyrosine kinase 3-internal tandem duplication mutation in solitary bone plasmacytoma: A case report.World journal of clinical cases · 2020Article
- Acute Promyelocytic Leukemia After Radium-223 Exposure for Prostate Cancer in a Chemotherapy-Naïve Patient.Nuclear medicine and molecular imaging · 2020Article
- Risk of subsequent myeloid neoplasms after radiotherapy treatment for a solid cancer among adults in the United States, 2000-2014.Leukemia · 2018Article
- Myelodysplasia-related acute myeloid leukemia and acute promyelocytic leukemia: concomitant occurrence of two molecularly distinct diseases.Hematology reports · 2018Article
- Therapy-related myeloid neoplasms: clinical perspectives.OncoTargets and therapy · 2018Review
- Article
- Acute promyelocytic leukemia after renal transplant and filgrastim treatment for neutropenia.Proceedings (Baylor University. Medical Center) · 2016Article
- Chromosomal abnormality of acute promyelocytic leukemia other thanBMC clinical pathology · 2016Article
- CD34(+) therapy-related acute promyelocytic leukemia in a patient previously treated for breast cancer.Stem cell investigation · 2016Article
- Global characteristics of childhood acute promyelocytic leukemia.Blood reviews · 2015Review
- Evaluation of prognostic factors in patients with therapy-related acute myeloid leukemia.Blood research · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Acute promyelocytic leukemia (APL) is a relatively common form of acute myeloid leukemia (AML) that has an excellent prognosis. In contrast, secondary acute myeloid leukemias, including therapy-related AML and AML with myelodysplasia-related changes, have a relatively poor prognosis. We identified 9 cases of APL at our institution in which there was a history of chemotherapy, radiotherapy, chronic immunosuppression, or antecedent myelodysplastic syndrome. The clinical and pathologic findings in these cases of secondary APL were compared with the clinical and pathologic findings in cases of de novo APL. We found that secondary and de novo APL had abnormal promyelocytes with similar morphologic and immunophenotypic features, comparable cytogenetic findings, comparable rates of FMS-like tyrosine kinase mutations, and similar rates of recurrent disease and death. These data suggest that secondary APL is similar to de novo APL and, thus, should be considered distinct from other secondary acute myeloid neoplasms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.